Clinical trials: Short Bowel Syndrome
Short Bowel Syndrome
A Study With Teduglutide (Revestive®) in Adults With Short Bowl Syndrome
The main aims of the study are to assess the safety profile of teduglutide (Revestive®) as well as how many people with Short Bowl Syndrome experience a reduction of parenteral support when treated with teduglutide (Revestive®).
- Trial name
- T-Rex (NCT04883606)
- Where
- Spain
- Volunteers
- 65 people
- Sponsor
- Takeda
Short Bowel Syndrome (SBS)
A Study of Teduglutide (Revestive®) in Participants With Short Bowel Syndrome (SBS) in Canada
The main aim of this study is to assess the effectiveness and side effects of teduglutide (Revestive®) in real-world clinical practice setting in adult participants with intestinal failure due to short bowel syndrome (SBS-IF) in…
- Trial name
- NCT05371028
- Testing
- Non-interventional Study
- Where
- Canada
- Volunteers
- 52 people
- Sponsor
- Takeda
Short Bowel Syndrome
Safety and Efficacy Study in Infant With SBS
The objective of this clinical study is to evaluate the efficacy and safety of NTRA-9620 compared with placebo in pediatric subjects (aged 28 weeks postmenstrual age to 52 weeks old) with SBS following surgical resection
- Trial name
- GIFT (NCT02865122)
- Testing
- NTRA-9620
- Where
- 8 sites in United States
- Volunteers
- 2 people
- Sponsor
- Elgan Pharma Ltd.
Short Bowel Syndrome
Registry for Participants With Short Bowel Syndrome
This is a global prospective, observational, multi-center registry to evaluate the long-term safety profile for participants with short bowel syndrome (SBS) who are treated with teduglutide in a routine clinical setting.
- Trial name
- NCT01990040
- Where
- United States
- Volunteers
- 1,806 people
- Sponsor
- Shire
Short Bowel Syndrome
Long-term Safety and Efficacy Study of Teduglutide in Pediatric Participants With Short Bowel Syndrome (SBS)
This study will follow participants who completed the TED-C14-006 study. The purpose of this study is to evaluate the long-term safety and efficacy of teduglutide in pediatric participants with Short Bowel Syndrome (SBS).
- Trial name
- NCT02954458
- Testing
- TED, SOC, Syringe
- Where
- 22 sites in United States, Belgium and 4 more
- Volunteers
- 61 people
- Sponsor
- Shire
Short Bowel Syndrome (SBS)
Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome
The purpose of this study is to understand the safety and efficacy of twice weekly glepaglutide 10 mg in adult patients with short bowel syndrome (SBS), who were previously enrolled in the EASE SBS 2 or EASE SBS 3 trials.
- Trial name
- EASE SBS 6 (NCT07228403)
- Testing
- Glepaglutide 10 mg
- Where
- 16 sites in United States, Belgium and 5 more
- Volunteers
- 28 people
- Sponsor
- Zealand Pharma
Short Bowel Syndrome
Safety, Efficacy, PD of FE203799 in Short Bowel Syndrome on Parenteral Support
Part A:once weekly dosing for 4 weeks in patients with short bowel syndrome who require total parenteral nutrition; patients will complete period 1 and after a 6-10 week wash-out, they will enter period 2 (active treatment and…
- Trial name
- NCT03415594
- Testing
- FE203799 GLP-2 analogue
- Where
- Denmark
- Volunteers
- 8 people
- Sponsor
- GlyPharma Therapeutics
Short Bowel Syndrome (SBS)
Retrospective Study on Participants With Short Bowel Syndrome and Chronic Intestinal Failure That Underwent Transplantation in Brazil
The main aim of this study is to capture management and treatment outcome data in participants with short bowel syndrome and chronic intestinal failure (SBS-IF) that underwent intestinal transplantation in Brazil.
- Trial name
- NCT05113082
- Where
- Brazil
- Volunteers
- 7 people
- Sponsor
- Takeda
Short Bowel Syndrome (SBS), SBS Associated With Intestinal Failure (SBS-IF)
A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF)
This Phase 3 placebo-controlled study is planned to further investigate the efficacy, safety, and tolerability of apraglutide in the overall SBS-IF (short bowel syndrome associated with intestinal failure) population during 24…
- Trial name
- STARS-2 (NCT07742735)
- Testing
- Apraglutide
- Where
- 94 sites in United States, Argentina and 20 more
- Volunteers
- 124 people
- Sponsor
- VectivBio AG
Short Bowel Syndrome, SBS
A Clinical Study of FT1 in Patients With Short Bowel Syndrome
The goal of this clinical trial is to learn if FT1 is safe and works to treat short bowel syndrome (SBS) in adults. It will also learn about the PK/PD profile of FT1.
- Trial name
- NCT07704047
- Testing
- FT1
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Chongqing Peg-Bio Biopharm Co., Ltd.
Short Bowel Syndrome
Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS)
This study is a 2-year open label extension study to collect long term efficacy and safety data from patients who have completed the 24-weeks of study drug dosing in CL0600-020.
- Trial name
- NCT00930644
- Testing
- teduglutide
- Where
- 23 sites in United States, Canada and 7 more
- Volunteers
- 88 people
- Sponsor
- Shire
Short Bowel Syndrome
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS
The primary objective of the trial is to evaluate the long-term safety of glepaglutide treatment in patients with short bowel syndrome (SBS). Glepaglutide is the International Nonproprietary Name and USAN for ZP1848.
- Trial name
- EASE SBS 2 (NCT03905707)
- Testing
- glepaglutide
- Where
- 27 sites in United States, Belgium and 7 more
- Volunteers
- 150 people
- Sponsor
- Zealand Pharma
Metabolic Syndrome
Effects of Probiotics on Metabolic Syndrome ,Intestinal Microflora and SCFA.
The improvement effects of GLAC biotech probiotics contains 5 specialized strains on the biochemical analysis and gut microbiota will be verified in the clinical trial through cooperation with the ADPRC.
- Trial name
- NCT06183801
- Testing
- Probiotics 1, Probiotics 2, Probiotics 3
- Where
- Taiwan
- Volunteers
- 82 people
- Sponsor
- Glac Biotech Co., Ltd
Short Bowel Syndrome
Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 Study
The purpose of this study is to evaluate the safety and efficacy of teduglutide treatment of children with short bowel syndrome (SBS) who completed the TED-C13-003 study over a long-term period.
- Trial name
- NCT02949362
- Testing
- Teduglutide, SOC
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 29 people
- Sponsor
- Shire
Short Bowel Syndrome
The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome
The purpose of this trial is to investigate the long-term effect of glepaglutide on the intestinal absorption, nutritional status of participants with Short Bowel Syndrome (SBS).
- Trial name
- EASE SBS 4 (NCT04991311)
- Testing
- Glepaglutide
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- Zealand Pharma
Short Bowel Syndrome
A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome
The main aim of the study is to assess how well teduglutide works over 24 weeks in Chinese adult participants with short bowel syndrome (SBS) who need parenteral support and to see how much it can reduce the amount of parenteral…
- Trial name
- NCT06973304
- Testing
- Teduglutide
- Where
- 4 sites in China
- Volunteers
- 13 people
- Sponsor
- Takeda
Short Bowel Syndrome
An Extension Study of Teduglutide in Japanese Participants With Short Bowel Syndrome Who Completed 24 Weeks of Treatment in SHP633-306 or TED-C14-004
The purpose of this clinical study is to evaluate the long-term safety and efficacy of teduglutide in Japanese participants with PN/IV (parenteral nutrition/intravenous)-dependent SBS (short bowel syndrome) who completed…
- Trial name
- NCT03596164
- Testing
- Teduglutide, Syringe, Needle
- Where
- 5 sites in Japan
- Volunteers
- 11 people
- Sponsor
- Takeda
Short Bowel Syndrome
Safety, Efficacy and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age With Short Bowel Syndrome
The purpose of the study is to evaluate the safety, efficacy/pharmacodynamics (PD) and pharmacokinetics (PK) of teduglutide treatment in infants with short bowel syndrome (SBS) dependent on parenteral (PN) support.
- Trial name
- NCT03571516
- Testing
- Teduglutide, Standard Medical Therapy, Syringe
- Where
- 8 sites in Finland, France and 2 more
- Volunteers
- 10 people
- Sponsor
- Shire
Short Bowel Syndrome
Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.
The primary objective of the trial is to assess long-term safety and tolerability of apraglutide in subjects with SBS-IF.
- Trial name
- STARS extend (NCT05018286)
- Testing
- Apraglutide
- Where
- 66 sites in United States, Argentina and 16 more
- Volunteers
- 158 people
- Sponsor
- VectivBio AG
Short Bowel Syndrome
Proof of Concept Study in Patients With Short Bowel Syndrome
This is a Phase I/II. proof of concept, open label, two-dose, dose escalation study of NM-002 in adult patients with SBS who previously responded to exenatide.
- Trial name
- NCT04379856
- Testing
- NM-002
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- 9 Meters Biopharma, Inc.